* covid-19 disease requiring the use of supplemental oxygen * electrocardiogram (ecg) tracing with qtc interval \> 450 ms for men, \> 470 ms for women (fridericia algorithm recommended) * bradycardia (\< 50 beats/min) * history of cardiac disease (eg. congestive heart failure, myocardial infarction) * history of glucose-6-phosphate dehydrogenase (g6pd) deficiency * women who are pregnant or breastfeeding * concurrent antimicrobial therapy * known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds * hydroxychloroquine use within 2 months before enrollment * history of severe skin reactions such as sevens-johnson syndrome and toxic epidermal necrolysis * history of retinopathy * history of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death * history of severe renal disease (treatment with dialysis or phosphate binders) or hepatic impairment the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

* covid-19 disease requiring the use of supplemental oxygen * electrocardiogram (ecg) tracing with qtc interval \> 450 ms for men, \> 470 ms for women (fridericia algorithm recommended) * bradycardia (\< 50 beats/min) * history of cardiac disease (eg. congestive heart failure, myocardial infarction) * history of glucose-6-phosphate dehydrogenase (g6pd) deficiency * women who are pregnant or breastfeeding * concurrent antimicrobial therapy * known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds * hydroxychloroquine use within 2 months before enrollment * history of severe skin reactions such as sevens-johnson syndrome and toxic epidermal necrolysis * history of retinopathy * history of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death * history of severe renal disease (treatment with dialysis or phosphate binders) or hepatic impairment the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- covid-19 disease requiring the use of supplemental oxygen - electrocardiogram (ecg) tracing with qtc interval > 450 ms for men, > 470 ms for women (fridericia algorithm recommended) - bradycardia (< 50 beats/min) - history of cardiac disease (eg. congestive heart failure, myocardial infarction) - history of glucose-6-phosphate dehydrogenase (g6pd) deficiency - women who are pregnant or breastfeeding - concurrent antimicrobial therapy - known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds - hydroxychloroquine use within 2 months before enrollment - history of severe skin reactions such as sevens-johnson syndrome and toxic epidermal necrolysis - history of retinopathy - history of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death - history of severe renal disease (treatment with dialysis or phosphate binders) or hepatic impairment the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- covid-19 disease requiring the use of supplemental oxygen - electrocardiogram (ecg) tracing with qtc interval > 450 ms for men, > 470 ms for women (fridericia algorithm recommended) - bradycardia (< 50 beats/min) - history of cardiac disease (eg. congestive heart failure, myocardial infarction) - history of glucose-6-phosphate dehydrogenase (g6pd) deficiency - women who are pregnant or breastfeeding - concurrent antimicrobial therapy - known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds - hydroxychloroquine use within 2 months before enrollment - history of severe skin reactions such as sevens-johnson syndrome and toxic epidermal necrolysis - history of retinopathy - history of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death - history of severe renal disease (treatment with dialysis or phosphate binders) or hepatic impairment the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.